Claims for Patent: 8,409,578

Summary for Patent: 8,409,578

Title:	Methods for treating bone loss with antibodies to OPGL
Abstract:	Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
Inventor(s):	Boyle; William J. (Thousand Oaks, CA), Martin; Francis H. (Newbury Park, CA), Corvalan; Jose R. (Foster City, CA), Davis; C. Geoffrey (Burlingame, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA)
Application Number:	13/296,201
Patent Claims:	1. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein the heavy chain and light chain form an antibody that interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 2. The method of claim 1, wherein: a) the heavy chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 13; and b) the light chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 14. 3. The method of claim 2, wherein the heavy chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 13 and the light chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 14. 4. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO: 13, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 5. The method of claim 4, wherein the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467. 6. The method of claim 4, wherein the heavy chain consists of the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467. 7. The method of claim 4, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO:14. 8. The method of claim 5, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO:14. 9. The method of claim 6, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO:14. 10. The method of claim 4, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 11. The method of claim 6, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 12. The method of claim 4, wherein the light chain consists of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 13. The method of claim 5, wherein the light chain consists of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 14. The method of claim 4, wherein the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the light chain comprises the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 15. The method of claim 4, wherein the heavy chain consists of the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the light chain consists of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 16. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO:14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 17. The method of claim 16, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 18. The method of claim 16, wherein the light chain consists of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 19. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 20. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:13 and the second polynucleotide encodes a light chain, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 21. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO: 14, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 22. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO: 4, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). 23. The method of claim 20, wherein the second polynucleotide encodes a light chain comprising the amino acid sequence set forth in SEQ ID NO:14. 24. The method of any one of claims 1, 4, 16, 19, 20, 23, 21, and 22, wherein the bone loss is associated with at least one condition selected from an osteopenic disorder, an inflammatory condition, an autoimmune condition, rheumatoid arthritis, and cancer. 25. The method of claim 24, wherein the bone loss is associated with an osteopenic disorder, and wherein the method further comprises administering at least one additional therapeutic agent selected from a bone morphogenic factor, a transforming growth factor-.beta. (TGF-.beta.), a parathyroid hormone, an analog of a parathyroid hormone, a parathyroid hormone related protein, an analog of a parathyroid hormone related protein, a prostaglandin, a bisphosphonate, an alendronate, fluoride, calcium, a fibroblast growth factor (FGF), and an FGF modulator. 26. The method of claim 24, wherein the bone loss is associated with an inflammatory condition, and wherein the method further comprises administering at least one additional therapeutic agent selected from an interleukin-1 (IL-1) inhibitor, IL-1ra, Kineret.TM., anakinra, a TNF.alpha. inhibitor, a soluble TNF.alpha. receptor, Enbrel.TM., etanercept, an anti-TNF.alpha. antibody, Remicade.TM., infliximab, a D2E7 antibody, a non-steroidal anti-inflammatory drug (NSAID), a COX-2 inhibitor, Celebrex.TM., celecoxib, Vioxx.TM., rofecoxib, and leflunomide. 27. The method of claim 24, wherein the bone loss is associated with an autoimmune condition, and wherein the method further comprises administering at least one additional therapeutic agent selected from an interleukin-1 (IL-1) inhibitor, IL-1ra, Kineret.TM., anakinra, a TNF.alpha. inhibitor, a soluble TNF.alpha. receptor, Enbrel.TM., etanercept, an anti-TNF.alpha. antibody, Remicade.TM., infliximab, a D2E7 antibody, methotrexate, a soluble form of CTLA4, and a modulator of glucocorticoid receptor. 28. The method of claim 24, wherein the bone loss is associated with rheumatoid arthritis, and wherein the method further comprises administering at least one additional therapeutic agent selected from an interleukin-1 (IL-1) inhibitor, IL-1ra, Kineret.TM., anakinra, a TNF.alpha. inhibitor, a soluble TNF.alpha. receptor, Enbrel.TM., etanercept, an anti-TNF.alpha. antibody, Remicade.TM., infliximab, a D2E7 antibody, a non-steroidal anti-inflammatory drug (NSAID), a COX-2 inhibitor, Celebrex.TM., celecoxib, Vioxx.TM., rofecoxib, leflunomide, methotrexate, a soluble form of CTLA4, and a modulator of glucocorticoid receptor. 29. The method of claim 24, wherein the bone loss is associated with cancer, and wherein the method further comprises administering at least one additional therapeutic agent selected from a keratinocyte growth factor (KGF), a KGF-related molecule, a KGF modulator, an anti-Her2 antibody, an anti-CDC20 antibody, and an anti-EGFR antibody, and a PAF antagonist. 30. The method of claim 24, wherein the bone loss is associated with cancer, and wherein the method further comprises administering at least one of radiation therapy and chemotherapy. 31. The method of claim 24, wherein the bone loss is associated with cancer selected from at least one of breast cancer, prostate cancer, thyroid cancer, kidney cancer, lung cancer, esophageal cancer, rectal cancer, bladder cancer, cervical cancer, ovarian cancer, and liver cancer, and gastrointestional tract cancer. 32. The method of any one of claims 1, 4, 16, 19, 20, 23, 21, and 22, wherein the bone loss is associated with a solid tumor. 33. The method of any one of claims 1, 4, 16, 19, 20, 23, 21, and 22, wherein the bone loss is associated with a metastatic tumor. 34. The method of any one of claims 1, 4, 16, 19, 20, 23, 21, and 22, wherein the bone loss is associated with at least one condition selected from osteoporosis, Paget's disease, osteomyelitis, hypercalcemia, osteopenia, and osteonecrosis. 35. The method of any one of claims 1, 4, 16, 19, 20, 23, 21, and 22, wherein the antibody is a fully human antibody. 36. The method of any one of claims 1, 4, 16, 19, 20, 23, 21, and 22, wherein the antibody is selected from a Fab antibody, a Fab' antibody, a F(ab').sub.2 antibody, and a single-chain scFv antibody.

Details for Patent 8,409,578

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2021-06-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2021-06-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2021-06-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2021-06-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2021-06-26

International Patent Family for US Patent 8,409,578

Country	Patent Number	Estimated Expiration
Argentina	034637
Austria	464068
Australia	2002320157
Australia	2008261137
Australia	2012216429